{"id":"https://genegraph.clinicalgenome.org/r/570a865b-4a49-4dd2-96bf-7535077f5288v1.0","type":"EvidenceStrengthAssertion","dc:description":"ATP11A was first reported in relation to autosomal dominant nonsyndromic hearing loss in 2022 (Pater et al., PMID: 35278131). ATP11A-related hearing loss is slowly progressive, nonsyndromic, and sensorineural. Variants in ATP11A have been reported in individuals with the following disease entities: auditory neuropathy, autosomal dominant 2 (MIM: 620384), leukodystrophy, hypomyelinating, 24 (MIM:619851), and deafness, autosomal dominant 84 (MIM:619810). Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no difference in molecular mechanism, phenotypic variability, or inheritance pattern between auditory neuropathy, autosomal dominant 2 and deafness, autosomal dominant 84. Therefore, the disease entities have been lumped into one term, autosomal dominant nonsyndromic hearing loss. We have split out leukodystrophy, hypomyelinating, 24 and this will be addressed by a separate GCEP.\n\nOne intronic, one frameshift, and one large deletion variants that have been reported in four probands in two publications (PMIDs: 35278131, 36300302) are included in this curation. The mechanism of pathogenicity is unknown at this time, but the three known variants all caused splicing defects affecting the last or second to last exon, most likely leading to a truncated protein. This gene-disease relationship is also supported by expression studies, a conditional knock-out mouse model, and a loss of function zebrafish model; However, the model organisms may not recapitulate the mechanism of disease in humans, as the proposed mechanism in humans in haploinsufficiency (PMIDs: 36300302, 40223426). In summary, there is moderate evidence to support this gene-disease relationship. While more evidence is needed to establish this relationship definitively, no convincing contradictory evidence has emerged. This classification was approved by the ClinGen Hearing Loss GCEP on the meeting date May 21st, 2025 (SOP Version 11).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/570a865b-4a49-4dd2-96bf-7535077f5288","GCISnapshot":"https://genegraph.clinicalgenome.org/r/d997f862-6a13-4da1-93cb-8fab590f87a8","calculatedEvidenceStrength":"Moderate","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/d997f862-6a13-4da1-93cb-8fab590f87a8_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10007","date":"2025-05-21T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/d997f862-6a13-4da1-93cb-8fab590f87a8_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10007","date":"2025-07-24T14:13:38.480Z","role":"Publisher"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d997f862-6a13-4da1-93cb-8fab590f87a8_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0618c53d-856d-4ba3-acbc-409798bcef65","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0618c53d-856d-4ba3-acbc-409798bcef65_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"A minigene assay did not show aberrant splicing, but sequencing of the normal and mutant minigene products demonstrated that the insertion adds 8 bp to exon 28, leading to a frameshift at amino acid 1110","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/0618c53d-856d-4ba3-acbc-409798bcef65_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35278131","allele":{"id":"https://genegraph.clinicalgenome.org/r/d5a03d2d-7c0a-4a2a-b012-bc47f6678c7a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000013.11:g.112875936_112875943dup","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573053780"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/353e6ce9-b0c7-4243-bf21-2f25874b3d39","type":"EvidenceLine","dc:description":"The variant is a 5500 bp deletion that encompasses the last coding exon, leading to the inclusion of a pseudoexon of 117 bp (exon 29neo). Because it does not escape NMD, the deletion variant was downgraded to 0.5 points, but an additional 0.5 points was given for functional evidence.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/353e6ce9-b0c7-4243-bf21-2f25874b3d39_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Intake of NBD-labeled phosphatidylserine in cells overexpressing ATP11A carrying exon 29neo was significantly reduced compared with isoform 1 wildtype ATP11A and was similar to the null mutation ATP11AGlu186Gln, the empty vector and isoform 2 wildtype ATP11A","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/353e6ce9-b0c7-4243-bf21-2f25874b3d39_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36300302","allele":{"id":"https://genegraph.clinicalgenome.org/r/6bde194b-9797-4355-9c91-4b44beb656af","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_015205.3(ATP11A):c.*1526_*1644del","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3062284468"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/282dc439-a15d-4346-9674-3e0eda2c1ccf","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/282dc439-a15d-4346-9674-3e0eda2c1ccf_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Sequencing of cloned RT-PCR products show they retain 153 bp of intronic sequence at the 3â€²UTR of ATP11A and is consistent with the three aberrant higher-molecular weight products, showing RNA validation of aberrant splicing. ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/282dc439-a15d-4346-9674-3e0eda2c1ccf_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35278131","allele":{"id":"https://genegraph.clinicalgenome.org/r/3f2037a6-3e81-4b5b-8837-a6377710b6db","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_015205.3(ATP11A):c.*10-1227G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2695219032"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/d997f862-6a13-4da1-93cb-8fab590f87a8_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/94aff0bd-0ac8-43b8-9390-e311414a2558_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36300302","rdfs:label":"Chepurwar Family","estimatedLodScore":3.01,"family":{"id":"https://genegraph.clinicalgenome.org/r/94aff0bd-0ac8-43b8-9390-e311414a2558","type":"Family","rdfs:label":"Chepurwar Family","member":{"id":"https://genegraph.clinicalgenome.org/r/e42a3964-716b-4798-9c74-8b957da2d10e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36300302","rdfs:label":"Chepurwar_IV-1","allele":{"id":"https://genegraph.clinicalgenome.org/r/6bde194b-9797-4355-9c91-4b44beb656af"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001963","obo:HP_0000407","obo:HP_0000006","obo:HP_0003676"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/353e6ce9-b0c7-4243-bf21-2f25874b3d39_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":11,"phenotypes":["obo:HP_0003676","obo:HP_0000407","obo:HP_0000006","obo:HP_0001963"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/e42a3964-716b-4798-9c74-8b957da2d10e"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/d6b7a08c-fc06-4d03-8a77-1a1a9c3567c0_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35278131","rdfs:label":"Pater Family A","estimatedLodScore":1.2,"family":{"id":"https://genegraph.clinicalgenome.org/r/d6b7a08c-fc06-4d03-8a77-1a1a9c3567c0","type":"Family","rdfs:label":"Pater Family A","member":{"id":"https://genegraph.clinicalgenome.org/r/bd98840c-f92d-464b-b158-51ad61bb0aed","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35278131","rdfs:label":"Pater PID II-2","allele":{"id":"https://genegraph.clinicalgenome.org/r/d5a03d2d-7c0a-4a2a-b012-bc47f6678c7a"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0000407","obo:HP_0000006"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/0618c53d-856d-4ba3-acbc-409798bcef65_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":5,"phenotypes":["obo:HP_0000006","obo:HP_0000407"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/bd98840c-f92d-464b-b158-51ad61bb0aed"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/02414100-c66b-4b07-88ba-8a5a06b7619a_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35278131","rdfs:label":"Pater_NL family","estimatedLodScore":4.82,"family":{"id":"https://genegraph.clinicalgenome.org/r/02414100-c66b-4b07-88ba-8a5a06b7619a","type":"Family","rdfs:label":"Pater_NL family","member":{"id":"https://genegraph.clinicalgenome.org/r/653029f7-59d1-455d-b02a-ad04d95bcc8d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35278131","rdfs:label":"Pater PID IV-7","allele":{"id":"https://genegraph.clinicalgenome.org/r/3f2037a6-3e81-4b5b-8837-a6377710b6db"},"detectionMethod":"Genome-wide SNP genotyping and two-point linkage analysis performed for NL family","firstTestingMethod":"Linkage analysis","phenotypes":["obo:HP_0001730","obo:HP_0000407","obo:HP_0000006"],"secondTestingMethod":"Other","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/282dc439-a15d-4346-9674-3e0eda2c1ccf_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":17,"phenotypes":["obo:HP_0001730","obo:HP_0000006","obo:HP_0000407"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/653029f7-59d1-455d-b02a-ad04d95bcc8d"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/13c6aae7-bf4f-4f32-9142-85da701ee37d_family_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35278131","rdfs:label":"Pater Family B","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/13c6aae7-bf4f-4f32-9142-85da701ee37d","type":"Family","rdfs:label":"Pater Family B"},"phenotype":[{"id":"obo:HP_0000006"},{"id":"obo:HP_0000407"},{"id":"obo:HP_0003676"}],"phenotypePositiveAllelePositive":3}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":3}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":6.5},{"id":"https://genegraph.clinicalgenome.org/r/d997f862-6a13-4da1-93cb-8fab590f87a8_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d997f862-6a13-4da1-93cb-8fab590f87a8_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/220e4cb7-43a5-419b-a956-ba31ceb08a68","type":"EvidenceLine","dc:description":"This model has been downgraded because the human disease mechanism is not known to be loss of function","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b5e1d164-d6dc-4c10-bdd5-7fe9627c348b","type":"Finding","dc:description":"Like the human phenotype, the zebrafish showed hearing loss","dc:source":"https://pubmed.ncbi.nlm.nih.gov/40223426","rdfs:label":"Hawkey-Noble zebrafish","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/34356d68-92f3-4d75-9770-45a2eb6c859c","type":"EvidenceLine","dc:description":"This model has been downgraded since it is a knockout model, and the mechanism in humans is not known to be loss of function.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/31235caf-a7a1-41f6-93b7-421c230d563e","type":"Finding","dc:description":"Like the human phenotype, cKO mice showed age-progressive loss of spiral ganglion neurons and hearing loss","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36300302","rdfs:label":"Chepurwar_mouse model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/d997f862-6a13-4da1-93cb-8fab590f87a8_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/147faba7-0ab5-45ba-842d-b8debfa48be9","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8c0daaa5-e34d-4bf9-a0ed-a49fc18404cd","type":"Finding","dc:description":"The authors performed immunofluorescent labeling of whole-mount preparations and cryosections of the organ of Corti and cochlear nucleus in mice. Anti-ATP11A reliably and specifically labeled type I and type II spiral ganglion neurons (SGN), which connect the afferent ribbon synapses of inner hair cells (IHC) and outer hair cells (OHC) with neurons of the brainstem.\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36300302","rdfs:label":"Chepurwar_expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1.5}],"evidenceStrength":"Moderate","sequence":10859,"specifiedBy":"GeneValidityCriteria11","strengthScore":8,"subject":{"id":"https://genegraph.clinicalgenome.org/r/bk0RsSIVdnQ","type":"GeneValidityProposition","disease":"obo:MONDO_0019587","gene":"hgnc:13552","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_d997f862-6a13-4da1-93cb-8fab590f87a8-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}